The United States: Varubi (rolapitant) Injectable Emulsion: Health Care Provider Letter - Anaphylaxis and other serious hypersensitivity reactions (English Only)
The US Food and Drug Administration (FDA) announces that anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported in the postmarketing setting, some requiring hospitalization. These reactions have occurred during or soon after the infusion of Varubi (rolapitant) injectable emulsion. Most reactions have occurred within the first few minutes of administration. Symptoms of anaphylaxis can include wheezing or difficulty breathing; swelling of the face or throat; hives or flushing; itching; abdominal cramping, abdominal pain or vomiting; back pain or chest pain; hypotension or shock. 

Healthcare professionals must be vigilant for signs of hypersensitivity or anaphylaxis in all patients receiving Varubi (rolapitant) injectable emulsion, both during and following its administration. It is advised that healthcare professionals consult with patients to determine if the patient is hypersensitive to any component of the product (including soybean oil). Furthermore, as cross reactions to other allergens is possible, patients with known allergies to legumes or other related allergens should be monitored closely. Patients with a potential hypersensitivity should not be administered Varubi (rolapitant) injectable emulsion. 

Appropriate treatment should be available for immediate use in the event of an anaphylactic reaction during treatment with Varubi (rolapitant) injectable emulsion. 

If anaphylaxis or any other serious hypersensitivity/infusion reaction occurs, 
- administration of Varubi (rolapitant) injectable emulsion should be stopped immediately. 
- appropriate medical management (including epinephrine and or antihistamines) should be initiated, and 
- Varubi (rolapitant) injectable emulsion should be permanently discontinued. 

Please refer to the following website in FDA for details: 

In Hong Kong, the above product is not a registered pharmaceutical product. 

Ends/Wednesday, Jan 17, 2018 
Issued at HKT 16:00